CompletedNCT01303536
Ondansetron Added to an SSRI for Treatment-Resistant OCD
About this title
Read the official source — NCT01303536Medication studyAges 18–60Italy
Understand this study
Who was this study for?
Listed age limits: 18 years to 60 years.
- Listed locations
- FlorenceSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateDecember 2009
- Recruitment status
- Completed
- Enrollment listed in the registry
- 21
- Sponsor
- Institute of Neuroscience, Florence, Italy
- Sponsor type
- Research institute
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Italy
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT01303536
- Official title
Show the full official title
Ondansetron Augmentation in Treatment-resistant OCD
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedFlorence
Questions about this study
Who is behind this study?
The study sponsor is Institute of Neuroscience, Florence, Italy, a research institute.
Did this study involve medication?
Yes. The study involved medication, including Ondansetron.
Who was this study for?
Listed age limits: 18 years to 60 years.
Want to explore more studies?
Explore studiesRelated studies
Troriluzole added to treatment for obsessive-compulsive symptoms
Eficacia de agomelatina 25mg/día (con posibilidad de incremento a 50mg/día tras 8 semanas de tratamiento) por vía oral durante 16 semanas en pacientes con Trastorno Obsesivo Compulsivo // Efficacy...